Evaluation of Risk-Minimization Activities for Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg: A Cross-Sectional Physician Survey
August 2017
in “
Pharmaceutical medicine
”
Studysummary This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics. Our plain-language summary of this paper — not a Tressless recommendation.
The study assessed physicians' knowledge of the risks associated with Cyproterone Acetate 2 mg/Ethinylestradiol 35 µg (CPA/EE), particularly thromboembolism risk, and the impact of educational materials on this knowledge. The survey included 759 physicians from five European countries. Results indicated that while overall knowledge was high, with 89.3% aware of the increased thrombosis risk in the first year of CPA/EE use and over 95% recognizing symptoms of thrombosis and myocardial infarction, there were gaps in knowledge about contraindications, less common risk factors, and specific patient instructions for surgery or immobilization. Knowledge did not significantly vary by specialty, experience, or patient volume. Only 51% of physicians reported receiving educational materials, but those who did found them helpful. The study concluded that despite some physicians not receiving the materials, the high level of knowledge suggests that safety information is being effectively communicated through other channels.
